Picture of Genetic Technologies logo

GTG Genetic Technologies Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m+31.9%
3m-25.23%
6m-51.14%
1yr-60.01%
Volume Change (%)
10d/3m+0.28%
Price vs... (%)
52w High-66.25%
50d MA+15.03%
200d MA-33.71%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-256.17%
Return on Equity-160.47%
Operating Margin-152.21%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202430th Jun 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Genetic Technologies EPS forecast chart

Profile Summary

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor

Directors

Last Annual
June 30th, 2023
Last Interim
December 31st, 2023
Incorporated
January 5th, 1987
Public Since
July 30th, 1987
No. of Shareholders
4,846
No. of Employees
60
Sector
Healthcare Providers & Services
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
115,417,246

GTG Share Price Performance

Upcoming Events for GTG

Full Year 2024 Genetic Technologies Ltd Earnings Release

Similar to GTG

Picture of Apiam Animal Health logo

Apiam Animal Health

au flag iconAustralian Stock Exchange - SEATS

Picture of Artrya logo

Artrya

au flag iconAustralian Stock Exchange - SEATS

Picture of Australian Clinical Labs logo

Australian Clinical Labs

au flag iconAustralian Stock Exchange - SEATS

Picture of Cann logo

Cann

au flag iconAustralian Stock Exchange - SEATS

Picture of Capitol Health logo

Capitol Health

au flag iconAustralian Stock Exchange - SEATS

FAQ